{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["1ec68fca-e33b-45b1-bae0-9acdc2f2795b", "Q2", 400701094, "GOLDBUG STRATEGIES LLC", 194361, "GENOMIC HEALTH INC.", 2011, "second_quarter", "2011-07-05T17:12:29.537000-04:00", 110000.0, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/1ec68fca-e33b-45b1-bae0-9acdc2f2795b/\", \"filing_uuid\": \"1ec68fca-e33b-45b1-bae0-9acdc2f2795b\", \"filing_type\": \"Q2\", \"filing_type_display\": \"2nd Quarter - Report\", \"filing_year\": 2011, \"filing_period\": \"second_quarter\", \"filing_period_display\": \"2nd Quarter (Apr 1 - June 30)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/1ec68fca-e33b-45b1-bae0-9acdc2f2795b/print/\", \"filing_document_content_type\": \"text/html\", \"income\": \"110000.00\", \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"Sheila D. Walcoff, Esq. Founding Principal\", \"dt_posted\": \"2011-07-05T17:12:29.537000-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"9713 Key West Avenue Suite 250\", \"registrant_address_2\": null, \"registrant_different_address\": false, \"registrant_city\": \"Rockville\", \"registrant_state\": \"MD\", \"registrant_zip\": \"20850\", \"registrant\": {\"id\": 400701094, \"url\": \"https://lda.senate.gov/api/v1/registrants/400701094/\", \"house_registrant_id\": null, \"name\": \"GOLDBUG STRATEGIES LLC\", \"description\": \"Personal genomic services firm\", \"address_1\": \"510 Diamondback Drive #570\", \"address_2\": null, \"address_3\": null, \"address_4\": null, \"city\": \"Rockville\", \"state\": \"MD\", \"state_display\": \"Maryland\", \"zip\": \"20878\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"ULYANA KANITSKA\", \"contact_telephone\": \"+1 301-355-2661\", \"dt_updated\": \"2025-06-07T12:43:12.498936-04:00\"}, \"client\": {\"id\": 194361, \"url\": \"https://lda.senate.gov/api/v1/clients/194361/\", \"client_id\": 12, \"name\": \"GENOMIC HEALTH INC.\", \"general_description\": \"clinical laboratory\", \"client_government_entity\": false, \"client_self_select\": false, \"state\": \"CA\", \"state_display\": \"California\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": null, \"ppb_state_display\": null, \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2011-01-01\"}, \"lobbying_activities\": [{\"general_issue_code\": \"HCR\", \"general_issue_code_display\": \"Health Issues\", \"description\": \"FDA regulation of laboratory developed tests.\\nMedicare reimbursement for laboratory developed tests.\\nTricare payment of laboratory developed tests.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 53398, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"SHEILA\", \"nickname\": null, \"middle_name\": \"D\", \"last_name\": \"WALCOFF\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": \"Committee, US House Of Representatives\", \"new\": false}], \"government_entities\": [{\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"MMM\", \"general_issue_code_display\": \"Medicare/Medicaid\", \"description\": \"FDA regulation of laboratory developed tests.\\nMedicare reimbursement for laboratory developed tests.\\nTricare payment of laboratory developed tests.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 53398, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"SHEILA\", \"nickname\": null, \"middle_name\": \"D\", \"last_name\": \"WALCOFF\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": \"Committee, US House Of Representatives\", \"new\": false}], \"government_entities\": [{\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"MED\", \"general_issue_code_display\": \"Medical/Disease Research/Clinical Labs\", \"description\": \"FDA regulation of laboratory developed tests.\\nMedicare reimbursement for laboratory developed tests.\\nTricare payment of laboratory developed tests.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 53398, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"SHEILA\", \"nickname\": null, \"middle_name\": \"D\", \"last_name\": \"WALCOFF\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": \"Committee, US House Of Representatives\", \"new\": false}], \"government_entities\": [{\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["1ec68fca-e33b-45b1-bae0-9acdc2f2795b"], "units": {}, "query_ms": 6.9830999709665775, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}